Global Psoriatic Arthritis Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Type of Molecule;

Biologics and Small Molecules.

By Drug Class;

Non-steroidal Anti-inflammatory Drugs (NSAIDS), Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), and Others.

By Route Of Administration;

Oral, Parenteral, and Topical.

By Dosage Form;

Solid, Liquid and Semi-solid.

By Distribuation Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn334116643 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Psoriatic Arthritis Market (USD Million), 2021 - 2031

In the year 2024, the Global Psoriatic Arthritis Market was valued at USD 13,160.22 million. The size of this market is expected to increase to USD 21,691.68 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.4%.

The global psoriatic arthritis market is witnessing significant growth driven by several factors, including the increasing prevalence of psoriasis, rising awareness and diagnosis of psoriatic arthritis, and advancements in treatment options. Psoriatic arthritis is a chronic inflammatory condition that affects joints and is often associated with psoriasis, a skin disorder. As the prevalence of psoriasis continues to rise globally, the incidence of psoriatic arthritis is also increasing, driving demand for effective treatment options to manage symptoms and improve patients' quality of life.

Advancements in treatment modalities have transformed the management of psoriatic arthritis, offering patients a range of therapeutic options to alleviate symptoms and prevent disease progression. Traditional treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) have been supplemented by biologic agents and targeted synthetic DMARDs, which specifically inhibit inflammatory pathways involved in psoriatic arthritis. These innovative therapies have demonstrated significant efficacy in reducing joint inflammation, preserving joint function, and improving patient-reported outcomes, fueling market growth.

Moreover, the expansion of the biosimilars market presents opportunities for cost-effective alternatives to branded biologic drugs used in the treatment of psoriatic arthritis. Biosimilars offer comparable efficacy and safety profiles to their reference products while providing more affordable treatment options for patients and healthcare systems. As biosimilar versions of key biologic agents become available, market competition is expected to increase, driving down treatment costs and expanding access to psoriatic arthritis therapies. Overall, with ongoing research and development efforts and the expansion of biosimilar options, the global psoriatic arthritis market is poised for continued growth in the coming years.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type of Molecule
    2. Market Snapshot, By Drug Class
    3. Market Snapshot, By Route Of Administration
    4. Market Snapshot, By Dosage Form
    5. Market Snapshot, By Distribuation Channel
    6. Market Snapshot, By Region
  4. Global Psoriatic Arthritis Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Prevalence of Psoriasis
        2. Rising Awareness and Diagnosis of Psoriatic Arthritis
        3. Advancements in Treatment Modalities
      2. Restraints
        1. High Cost of Biologic Therapies
        2. Side Effects Associated with Treatments
        3. Stringent Regulatory Requirements
      3. Opportunities
        1. Expansion of Biosimilars Market
        2. Personalized Medicine Approaches
        3. Integration of Digital Health Technologies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Psoriatic Arthritis Market, By Type of Molecule, 2021 - 2031 (USD Million)
      1. Biologics
      2. Small molecules
    2. Global Psoriatic Arthritis Market, By Type of Molecule Drug Class, 2021 - 2031 (USD Million)
      1. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
      2. Non-biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
      3. Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs)
      4. Others
    3. Global Psoriatic Arthritis Market, By Type of Molecule Route Of Administration, 2021 - 2031 (USD Million)
      1. Oral
      2. Parenteral
      3. Topical
    4. Global Psoriatic Arthritis Market, By Dosage Form, 2021 - 2031 (USD Million)
      1. Solid
      2. Liquid
      3. Semi-solid
    5. Global Psoriatic Arthritis Market, By Type of Molecule Distribuation Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    6. Global Psoriatic Arthritis Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AbbVie Inc.
      2. Amgen Inc.
      3. Bristol Myers Squibb Company
      4. Johnson & Johnson Services, Inc.
      5. Novartis AG
      6. Pfizer Inc.
      7. UCB S.A.
      8. Eli Lilly and Company
      9. Celgene Corporation
      10. AstraZeneca PLC
  7. Analyst Views
  8. Future Outlook of the Market